Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
44.5 EUR | -0.67% | +0.91% | +71.15% |
Apr. 30 | Transcript : AlzChem Group AG, Q1 2024 Earnings Call, Apr 30, 2024 | |
Apr. 30 | AlzChem Group AG Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The company's attractive earnings multiples are brought to light by a P/E ratio at 11.12 for the current year.
- The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- The group usually releases upbeat results with huge surprise rates.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Diversified Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+71.15% | 495M | C+ | ||
+1.05% | 75.73B | B | ||
-1.33% | 47.26B | A- | ||
+5.71% | 33.92B | C | ||
+12.26% | 18.48B | B | ||
+11.69% | 11.79B | A- | ||
-1.82% | 10.72B | - | ||
-21.77% | 10.29B | B | ||
+1.06% | 9.22B | A- | ||
-8.06% | 8.23B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ACT Stock
- Ratings AlzChem Group AG